Do general practitioners follow treatment recommendations from guidelines in their decisions on heart failure management? A cross-sectional study

BMJ Open

Volumn 3, Issue 9, 2013, Pages

  Swennen, Maartje H J ^a   Rutten, Frans H ^a   Kalkman, Cor J ^a   Van Der Graaf, Yolanda ^a   Sachs, Alfred P E ^a   Van Der Heijden, Geert J M G ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL DECISION MAKING; CROSS-SECTIONAL STUDY; DRUG DOSE TITRATION; EVIDENCE BASED MEDICINE; FEMALE; GENERAL PRACTITIONER; HEART EJECTION FRACTION; HEART FAILURE; HUMAN; LOW DRUG DOSE; MALE; MEDICAL EDUCATION; MULTIPLE CHOICE TEST; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PRESCRIPTION; VIGNETTE;

EID: 84885353161     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2013-002982     Document Type: Article

References (29)

1. McMurray JJ, Adamopoulos S, Anker S.D., et al ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012;14:803-69.
2. Calvert MJ, Shankar A, McManus R.J., et al Evaluation of the management of heart failure in primary care. Fam Pract 2009;26:145-53.
3. Koschack J, Jung HH, Scherer M, et al Prescriptions of recommended heart failure medications can be correlated with patient and physician characteristics. IntJ Clin Pract 2009;63:226-32.
4. Remme WJ. Filling the gap between guidelines and clinical practice in heart failure treatment: still a far cry from reality. Eur J Heart Fail 2007;9:1143-5. (Pubitemid 350148275)
5. Teerlink JR. Ivabradine in heart failure-no paradigm SHIFT⋯yet. Lancet 2010;376:847-9.
6. Sood R, Sood A, Ghosh AK Non-evidence-based variables affecting physicians' test-ordering tendencies: a systematic review. Neth J Med 2007;65:167-77. (Pubitemid 47161618)
7. Landon BE, Normand SL, Meara E, et al The relationship between medical practice characteristics and quality of care for cardiovascular disease. Med Care Res Rev 2008;65:167-86. (Pubitemid 351350618)
8. Reid RO, Friedberg MW, Adams J.L., et al Associations between physician characteristics and quality of care. Arch Intern Med 2010;170:1442-9.
9. Kjekshus J, Apetrei E, Barrios V., et al Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007;357:2248-61. (Pubitemid 350190755)
10. Tavazzi L, Maggioni AP, Marchioli R, et al Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1231-9.
11. Fuat A, Hungin AP, Murphy JJ Barriers to accurate diagnosis and effective management of heart failure in primary care: qualitative study. BMJ 2003;326:196.
12. Phillips SM, Marton RL, Tofler GH Barriers to diagnosing and managing heart failure in primary care. Med J Aust 2004;181:78-81. (Pubitemid 39069568)
13. Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001;22:1527-60. (Pubitemid 32801300)
14. Salpeter SR, Ormiston TM, Salpeter EE Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005;4:CD003566. Assessed as up to date on 18 Aug 2010. http://summaries. cochrane.org/CD003566/are-cardioselective-beta-blockers-a-safe-and-effective- treatment-in-patients-with-chronic-obstructive-pulmonary-disease (accessed on 1 Mar 2013).
15. Salpeter SR, Ormiston TM, Salpeter EE Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005;4:CD003566.
16. Dickstein K, Cohen-Solal A, Filippatos G., et al ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008;29:2388-442.
17. From the Global Strategy for the Diagnosis, Management and Prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2011. http://www.goldcopd.org/ (accessed on 1 Mar 2013).
18. Peabody JW, Luck J, Glassman P., et al Measuring the quality of physician practice by using clinical vignettes: a prospective validation study. Ann Intern Med 2004;141:771-80.
19. Veloski J, Tai S, Evans A.S., et al Clinical vignette-based surveys: a tool for assessing physician practice variation. Am J Med Qual 2005;20:151-7. (Pubitemid 40880390)
20. Hoes AW, Voors AA, Rutten F.H., et al NHG standard Heart Failure. Huisarts Wet 2010;53:368-89.
21. Flores S, Reyes H, Perez-Cuevas R. Influence of physician factors on the effectiveness of a continuing medical education intervention. Fam Med 2006;38:511-17. (Pubitemid 44291120)
22. Pham T, Roy C, Mariette X., et al Effect of response format for clinical vignettes on reporting quality of physician practice. BMC Health Serv Res 2009;9:128.
23. CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994;90:1765-73.
24. Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997;349:375-80.
25. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-7.
26. CIBIS II Investigators and Committees. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13.
27. Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001;344:1659-67.
28. Krum H, Roecker EB, Mohacsi P, et al Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. JAMA 2003;289:712-18. (Pubitemid 37430365)
29. Packer M, Bristow MR, Cohn J.N., et al The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996;334: 1349-55. (Pubitemid 26152713)